Scintigraphic evaluation of intra‐arterial and intravenous regional limb perfusion of allogeneic bone marrow‐derived mesenchymal stem cells in the normal equine distal limb using<sup>99m</sup>Tc‐HMPAO

Compared with i.l. injection, RLP results in lower uptake but similar persistence of MSCs at the site of tendon lesions. A time dependent accumulation of MSCs was identified with i.a. RLP. The i.a. RLP appears more advantageous than the i.v. RLP in terms of distribution and uptake. However, the described i.a. technique produced arterial thrombosis and thus cannot currently be recommended for clinical use.

show abstract

“…and i.v. RLP of the limbs with lesions was similar to the persistence that was observed on the same horses before lesion induction .…”

Section: Resultssupporting

confidence: 79%

“…Scintigraphic tracking of technetium‐99 ( 99m Tc)‐labelled MSCs showed persistence in the normal equine distal limb after RLP at the level of the distal antebrachium for up to 24 h after administration . The i.a.…”

Section: Introductionmentioning

confidence: 99%

Distribution and persistence of technetium‐99 hexamethyl propylene amine oxime‐labelled bone marrow‐derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb

Solé

Spriet²,

Padgett³

et al. 2013

Equine Veterinary Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…In equine species, bone marrow (BM) is one of the most studied and used sources for obtaining adult stem cells [9,10]. However, adipose tissue (AT) is also an abundant and accessible source of MSCs that can provide a large number of cells required for use in cell therapy [11,12].…”

Section: Introductionmentioning

confidence: 99%

“…This lack of expression gives MSCs the potential to escape from T-cell recognition [33], making it feasible to create a cell bank for use in allogeneic therapies [5,10,18,31]. …”

Section: Introductionmentioning

confidence: 99%

Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential

et al. 2014

View full text Add to dashboard Cite

IntroductionStudies with mesenchymal stem cells (MSCs) are increasing due to their immunomodulatory, anti-inflammatory and tissue regenerative properties. However, there is still no agreement about the best source of equine MSCs for a bank for allogeneic therapy. The aim of this study was to evaluate the cell culture and immunophenotypic characteristics and differentiation potential of equine MSCs from bone marrow (BM-MSCs), adipose tissue (AT-MSCs) and umbilical cord (UC-MSCs) under identical in vitro conditions, to compare these sources for research or an allogeneic therapy cell bank.MethodsThe BM-MSCs, AT-MSCs and UC-MSCs were cultured and evaluated in vitro for their osteogenic, adipogenic and chondrogenic differentiation potential. Additionally, MSCs were assessed for CD105, CD44, CD34, CD90 and MHC-II markers by flow cytometry, and MHC-II was also assessed by immunocytochemistry. To interpret the flow cytometry results, statistical analysis was performed using ANOVA.ResultsThe harvesting and culturing procedures of BM-MSCs, AT-MSCs and UC-MSCs were feasible, with an average cell growth until the third passage of 25 days for BM-MSCs, 15 days for AT-MSCs and 26 days for UC-MSCs. MSCs from all sources were able to differentiate into osteogenic (after 10 days for BM-MSCs and AT-MSCs and 15 days for UC-MSCs), adipogenic (after 8 days for BM-MSCs and AT-MSCs and 15 days for UC-MSCs) and chondrogenic (after 21 days for BM-MSCs, AT-MSCs and UC-MSCs) lineages. MSCs showed high expression of CD105, CD44 and CD90 and low or negative expression of CD34 and MHC-II. The MHC-II was not detected by immunocytochemistry techniques in any of the MSCs studied.ConclusionsThe BM, AT and UC are feasible sources for harvesting equine MSCs, and their immunophenotypic and multipotency characteristics attained minimal criteria for defining MSCs. Due to the low expression of MHC-II by MSCs, all of the sources could be used in clinical trials involving allogeneic therapy in horses. However, the BM-MSCs and AT-MSCs showed fastest ‘‘in vitro’’ differentiation and AT-MSCs showed highest cell growth until third passage. These findings suggest that BM and AT may be preferable for cell banking purposes.

show abstract

“…Equine MSCs labeled with CM-DiL remained viable, retained their differentiation capacity and were identified within both naturally occurring and surgically created SDF tendon lesions up to 170 days postimplantation (Figure 2). No evidence of migration to adjacent areas of tendon was observed [82]. An alternative tracking method is to label MSCs with hexamethylpropyleneamine oxime (HMPAO) and Technetium99m (Tc99m), which allows in vivo tracking using a gamma camera.…”

Section: Cell Tracking and Fate After Implantationmentioning

confidence: 98%

The Current ‘State of Play’ of Regenerative Medicine in Horses: What the Horse Can Tell the Human

2014

View full text Add to dashboard Cite

The horse is an attractive model for many human age-related degenerative diseases of the musculoskeletal system because it is a large animal species that both ages and exercises, and develops naturally occurring injuries with many similarities to the human counterpart. It therefore represents an ideal species to use as a 'proving ground' for new therapies, most notably regenerative medicine. Regenerative techniques using cell-based therapies for the treatment of equine musculoskeletal disease have been in use for over a decade. This review article provides a summary overview of the sources, current challenges and problems surrounding the use of stem cell and non-cell-based therapy in regenerative medicine in horses and is based on presentations from a recent Havemeyer symposium on equine regenerative medicine where speakers are selected from leading authorities in both equine and human regenerative medicine fields from 10 different countries.

show abstract

Scintigraphic evaluation of intra‐arterial and intravenous regional limb perfusion of allogeneic bone marrow‐derived mesenchymal stem cells in the normal equine distal limb using^99mTc‐HMPAO

Abstract: Regional limb perfusion of MSCs might be used in cases where intralesional injection is not possible or in order to avoid iatrogenic needle damage. Further work is needed to assess the safety of IA RLP before its clinical use.

Cited by 54 publications

References 30 publications

Distribution and persistence of technetium‐99 hexamethyl propylene amine oxime‐labelled bone marrow‐derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb

Distribution and persistence of technetium‐99 hexamethyl propylene amine oxime‐labelled bone marrow‐derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb

Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential

The Current ‘State of Play’ of Regenerative Medicine in Horses: What the Horse Can Tell the Human

Contact Info

Product

Resources

About

Scintigraphic evaluation of intra‐arterial and intravenous regional limb perfusion of allogeneic bone marrow‐derived mesenchymal stem cells in the normal equine distal limb using99mTc‐HMPAO

Abstract: Regional limb perfusion of MSCs might be used in cases where intralesional injection is not possible or in order to avoid iatrogenic needle damage. Further work is needed to assess the safety of IA RLP before its clinical use.

Cited by 54 publications

References 30 publications

Distribution and persistence of technetium‐99 hexamethyl propylene amine oxime‐labelled bone marrow‐derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb

Distribution and persistence of technetium‐99 hexamethyl propylene amine oxime‐labelled bone marrow‐derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb

Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential

The Current ‘State of Play’ of Regenerative Medicine in Horses: What the Horse Can Tell the Human

Contact Info

Product

Resources

About

Scintigraphic evaluation of intra‐arterial and intravenous regional limb perfusion of allogeneic bone marrow‐derived mesenchymal stem cells in the normal equine distal limb using^99mTc‐HMPAO